Preclinical
Rutgers advances new mGluR5 agonists for preclinical myelin-repair development
Rutgers presented a series of more potent small-molecule mGluR5 agonists that promote myelin-protein production in human oligodendrocytes and have shown activity in animal models.
Practical availability: Preclinical — not available as a clinical intervention
What this means clinically
This is an early translational programme available for licensing or collaboration, not a clinical trial. Lead selection and optimisation are needed before human testing.
Source quality: Official university technology-transfer source • not clinical evidence
Tech transferRutgers Innovation Ventures ↗